Type I Diabetes

Metabolic Diseases
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
OPT101Phase 21 trial
Active Trials
NCT06964087Active Not RecruitingEst. Aug 2028
Sernova Biotherapeutics
1 program
1
Sernova Cell PouchPhase 1/21 trial
Active Trials
NCT01652911Terminated3Est. Mar 2016
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
NNC0361-0041Phase 11 trial
Active Trials
NCT04279613Completed47Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
T-TherapeuticsOPT101
Sernova BiotherapeuticsSernova Cell Pouch
Novo NordiskNNC0361-0041

Clinical Trials (3)

Total enrollment: 50 patients across 3 trials

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

Start: May 2025Est. completion: Aug 2028
Phase 2Active Not Recruiting

A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation

Start: Jun 2012Est. completion: Mar 20163 patients
Phase 1/2Terminated

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Start: Nov 2020Est. completion: Apr 202447 patients
Phase 1Completed

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space